Mesothelioma trial

Ethics and dissemination: Research ethics approval was granted by London - Camberwell St. We will submit the results for publication in a peer-reviewed journal. Keywords: chemotherapy; oncology; thoracic medicine; thoracic surgery. Re-use permitted under CC BY. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.

Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : April 12, See Contacts and Locations. Study Description. This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.

This study will recruit up to 18 patients whose MPM has progressed beyond first-line of palliative chemotherapy, with a platinum-based doublet, and now requires further palliative systemic treatment, or have declined first-line palliative chemotherapy, however must have been considered suitable for a platinum doublet chemotherapy. Detailed Description:.

Drug Information available for: Pembrolizumab. FDA Resources. Arms and Interventions. Pembrolizumab will be continued dosed at mg given every 3 weeks Drug: Pembrolizumab Pembrolizumab in week 1 dosed at mg prior to SBRT and then treatment with pembrolizumab will be continued dosed at mg given every 3 weeks.

An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at mg in week 1. Outcome Measures. To identify biomarkers that correlate with immunological response to therapy.

Eligibility Criteria. Patients must have a histological or cytological diagnosis of MPM. Patients should have non-radically treatable MPM i. Patients must have had disease progression or be intolerant of standard first-line palliative chemotherapy for MPM. Patients who have declined first-line palliative chemotherapy must have been suitable for platinum-doublet combination chemotherapy. Patient should have an ECOG performance status We hypothesised that this regimen would improve overall survival in MPM.

Methods: This open-label, randomised, phase 3 study CheckMate was run at hospitals across 21 countries. The median survival improvement for patients, though, was only modest for the most common subtype of disease when compared to standard chemotherapy.

The upcoming clinical trial will not only test the influence of OT on the checkpoint inhibitors but will be used to help identify more predictive biomarkers for TGF-beta. The long-range hope is to find better ways to counter defense mechanisms used by the tumor cells. Mesothelioma is a rare cancer with no definitive cure, diagnosed in an estimated 3, people within the U.

It is most often caused by the inhalation of toxic asbestos fibers. However, as required by the new California Consumer Privacy Act CCPA , you may record your preference to view or remove your personal information by completing the form below.

The information on this website is proprietary and protected. It is not a substitute for professional medical advice, diagnosis or treatment. Any unauthorized or illegal use, copying or dissemination will be prosecuted. Please read our privacy policy and disclaimer for more information about our website. This website and its content may be deemed attorney advertising. Prior results do not predict a similar outcome. For more information, visit our sponsors page. Your web browser is no longer supported by Microsoft.

Update your browser for more security, speed and compatibility. If you are looking for mesothelioma support, please contact our Patient Advocates at